Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 209 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care for Covid-19 Clear all
Withdrawn Phase 2 Interventional

COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

NCT05040776
View directory record Official record
Conditions
Thrombopenia, Covid19
Interventions
EP-7041 Injection
Drug
Lead sponsor
eXIthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Recruiting Not applicable Interventional

Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)

NCT03963622
View directory record Official record
Conditions
ARDS
Interventions
Respiratory Mechanics, Standard Ventilation Strategy
Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

NCT04346628
View directory record Official record
Conditions
Sars-CoV2, COVID-19
Interventions
Favipiravir, Placebo, Standard of care treatment
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy

NCT04590066
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu shot text messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
734,383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 7, 2026, 4:06 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 7, 2026, 4:06 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

NCT04445220
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Sepsis
Interventions
SBI-101
Biological
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 7, 2026, 4:06 AM EDT
Terminated Not applicable Interventional

CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19

NCT05530317
View directory record Official record
Conditions
Long COVID, COVID-19
Interventions
Cardiac Rehabilitation
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 7, 2026, 4:06 AM EDT
Completed No phase listed Observational

Feasibility Study of Hematology Parameters in COVID-19 Disease

NCT04816630
View directory record Official record
Conditions
Covid19, Sepsis, Adults, Emergency Department
Interventions
CBC-Diff Monocyte Volume Width Distribution
Device
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Impact of Colchicine and Low-dose Naltrexone on COVID-19

NCT04756128
View directory record Official record
Conditions
Covid19
Interventions
Colchicine 0.6 mg, Naltrexone
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Early Phase 1 Interventional

Convalescent Plasma in Pediatric COVID-19

NCT04458363
View directory record Official record
Conditions
COVID
Interventions
Convalescent Plasma (CP), Standard COVID-19 therapies
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
0 Years to 22 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 7, 2026, 4:06 AM EDT
Terminated Phase 2 Interventional Results available

Estradiol and Progesterone in Hospitalized COVID-19 Patients

NCT04865029
View directory record Official record
Conditions
Covid19
Interventions
Placebo injection and placebo pill, Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule
Other · Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Terminated Not applicable Interventional Results available

AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19

NCT04649775
View directory record Official record
Conditions
Corona Virus Infection, Respiratory Rate, Hypoxia, Covid19
Interventions
AirFLO2
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 7, 2026, 4:06 AM EDT
Terminated Phase 2 Interventional Results available

DISulfiram for COvid-19 (DISCO) Trial

NCT04485130
View directory record Official record
Conditions
Covid19
Interventions
Disulfiram, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Fresno, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Not applicable Interventional Results available

Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation

NCT04494867
View directory record Official record
Conditions
Covid19
Interventions
Core Warming, Standard of Care
Device · Other
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma for Patients With COVID-19

NCT04385199
View directory record Official record
Conditions
Coronavirus Infection, Coronavirus, COVID
Interventions
Convalescent plasma
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of UC-MSCs for COVID-19 Patients

NCT04355728
View directory record Official record
Conditions
Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care
Biological · Other
Lead sponsor
Camillo Ricordi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 7, 2026, 4:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)

NCT04762771
View directory record Official record
Conditions
Covid19
Interventions
Colchicine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 7, 2026, 4:06 AM EDT
Terminated Phase 2 Interventional

Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19

NCT04619706
View directory record Official record
Conditions
COVID-19
Interventions
FSD201, Placebo, Standard of Care for Covid-19
Drug · Other
Lead sponsor
Quantum Biopharma
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Miami, Florida • St. Petersburg, Florida • Idaho Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Atovaquone for Treatment of COVID-19

NCT04456153
View directory record Official record
Conditions
COVID-19
Interventions
Experimental Group, Placebo Group
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Study of Sargramostim in Patients With COVID-19

NCT04411680
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Sargramostim, Standard of care
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Fullerton, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects

NCT04880642
View directory record Official record
Conditions
COVID-19
Interventions
C21, Placebo
Drug
Lead sponsor
Vicore Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Orange, California • Winfield, Illinois • Fort Wayne, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Not listed Phase 1Phase 2 Interventional

Tolerability and Efficacy of RJX in Patients With COVID-19

NCT04708340
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions
Rejuveinix (RJX) Active Comparator, Placebo Comparator
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Houston, Texas • New Braunfels, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

NCT04662086
View directory record Official record
Conditions
Covid19
Interventions
Acebilustat, Camostat
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pleasanton, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

NCT04379518
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Recombinant Interferon Alfa-2b, Rintatolimod
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 7, 2026, 4:06 AM EDT